Non-Current Assets
Equity securities
Vertex Pharmaceuticals Equity securities increased by 22.9% to $20.4M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.6%, from $21.6M to $20.4M. Over 5 years (FY 2020 to FY 2025), Equity securities shows a downward trend with a -39.0% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
First reportedQ4 2019
Last reportedQ1 2026May 5, 2026
Metric ID:
ins_equity_securitiesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $154.1M | $218.76M | $230.9M | $155.3M | $71.1M | $122.8M | $116.8M | $148.1M | $52.6M | $46.4M | $46M | $43.4M | $30.6M | $33.4M | $36.6M | $21.6M | $27.9M | $9.4M | $16.6M | $20.4M |
| QoQ Change | — | +42.0% | +5.5% | -32.7% | -54.2% | +72.7% | -4.9% | +26.8% | -64.5% | -11.8% | -0.9% | -5.7% | -29.5% | +9.2% | +9.6% | -41.0% | +29.2% | -66.3% | +76.6% | +22.9% |
| YoY Change | — | — | — | — | -53.9% | -43.9% | -49.4% | -4.6% | -26.0% | -62.2% | -60.6% | -70.7% | -41.8% | -28.0% | -20.4% | -50.2% | -8.8% | -71.9% | -54.6% | -5.6% |
Range$9.4M – $230.9M
CAGR-34.7%
Avg YoY Growth-40.8%
Median YoY Growth-46.6%
Current Streak2 quarters growth
Equity securities at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's equity securities?
- Vertex Pharmaceuticals (VRTX) reported equity securities of $20.4M in Q1 2026.
- How has Vertex Pharmaceuticals's equity securities changed year-over-year?
- Vertex Pharmaceuticals's equity securities decreased by 5.6% year-over-year, from $21.6M to $20.4M.
- What is the long-term trend for Vertex Pharmaceuticals's equity securities?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's equity securities has grown at a -39.0% compound annual growth rate (CAGR), from $195.78M to $16.6M.